Peptides DB
Research-centric peptide and protocol reference hub

Retatrutide (LY3437943) record · updated 4h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 23 studiesJump to the evidenceCompare
What is Retatrutide (LY3437943) used for?

Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes

How it works: Triple GLP-1 / GIP / glucagon receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Retatrutide (LY3437943) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Current
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 35 registered trials. It describes the research record, not a recommendation.

Identity
NameRetatrutide (LY3437943)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMetabolic
Research levelModerate Research
Discovered byCurated master list · 2026
Pharmacology
MechanismTriple GLP-1 / GIP / glucagon receptor agonist
RouteSubcutaneous injection
Half-life~6 days
Time to peak—
DurationWeekly dosing (investigational)
Extraction confidence0.75
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 20, 2026. How this works →
Research stats
Total studies23
Human / animal / cellular7 / 4 / 0
Highest trial phasePhase 2
Years covered2023–2026
Latest study1d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

23 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.
FindingTotal weight loss of 58.8% (-108.7 kg) at 18 months.
Human2026Full text read0.80
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
FindingNot reported in abstract.
Animal2026Partial text0.60
Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.
FindingNot reported in abstract.
review2024Full text read0.70
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
FindingNot reported in abstract.
Animal2026Partial text0.50
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
FindingLimits of detection (LOD) were 6.14 ng/mL in plasma and 2.44 ng/mL in urine.
Human2023Full text read0.80
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
FindingLimits of detection in plasma were 6.14 ng/mL and in urine were 2.44 ng/mL.
Human2023Full text read0.80
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
FindingGlycemic improvement accounts for less than 15 to 20 percent of the reduction in major adverse cardiovascular events.
review2026Full text read0.70
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
FindingMean recoveries of 113.7-118.4% for marketed formulations.
—2026Full text read0.70
Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.
FindingPeak ketonaemia reached 4.3 mmol/L.
Human2023Full text read0.80
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
TakeawayNot reported in abstract.
review2026Title only0.10
Inotropic effects of retatrutide in isolated human atrial preparations.
FindingCumulatively applied retatrutide starting at 10 nM elevated FOC in HAP in a concentration- and time-dependent manner.
Human2026Full text read0.80
Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms
Finding7.2% body weight loss at 6-12 months for compounded retatrutide users, n=531, P=0.004.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Retatrutide (LY3437943) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Retatrutide (LY3437943) is discussed should be drawn from it.

Articles mentioning Retatrutide (LY3437943)